Trastuzumab biosimilar - CuraxysAlternative Names: CRX 02
Latest Information Update: 24 Jun 2015
At a glance
- Originator Curaxys
- Developer Curaxys; University of Cadiz
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action ERBB 2 receptor antagonists; Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Research Breast cancer
Most Recent Events
- 24 Jun 2015 Research is ongoing in Spain